Cite
HARVARD Citation
D'Souza, A. et al. (2022). A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology. 40 (31), pp. 3576-3586. [Online].